Latest Jerini Stories
DUBLIN, Ireland and LEXINGTON, Massachusetts, June 23, 2011 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the Pulmonary-Allergy Drugs Advisory Committee to the U.S.
PERTH, Australia and LELYSTAD, The Netherlands, May 10, 2011 /PRNewswire/ -- Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, and Pepscan Therapeutics, a Dutch biopharmaceutical firm focusing on protein mimicry technology, today announce that they have entered a Research Collaboration and Option Agreement to evaluate the combination of their complementary peptide technologies for drug discovery.
DUBLIN and LEXINGTON, Massachusetts, March 3, 2011 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the European Commission has approved FIRAZYR for self-administration after training in subcutaneous injection technique by a healthcare professional.
DUBLIN, Ireland and LEXINGTON, Massachusetts, February 28, 2011 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has submitted a complete response to the not approvable letter issued by the US Food and Drug Administration (FDA) to Jerini AG in April 2008 regarding its New Drug Application for FIRAZYR(R) (icatibant) for the treatment of acute attacks of hereditary angioedema (HAE).
Clinical trials from two international research teams have shown that icatibant, a new drug that blocks the action of an inflammatory protein known as bradykinin, is safe and effective in treating acute attacks of hereditary angioedema, a potentially life-threatening condition.
SurModics, a provider of surface modification and drug delivery technologies to the healthcare industry, has acquired a portfolio of intellectual property and collaborative drug delivery projects from PR Pharmaceuticals, a drug delivery company specializing in injectable, biodegradable sustained release formulations.
- Having a loud voice; vociferous; clamorous.
- Of grand or imposing sound.